Merck & Co. is preparing to launch a fresh clinical trial of an experimental Covid-19 treatment gained in a November deal after U.S. regulators said results from a small study weren’t sufficient to seek clearance.
The drugmaker will start a late-stage trial of MK-7110, a therapy for severely ill Covid patients, to address the concerns brought forth by the Food and Drug Administration, said Nick Kartsonis, senior vice president of clinical research for infectious diseases and vaccines at Merck Research Laboratories.
The additional work will put Merck months away from potentially filing for emergency clearance and bringing ...
